reading 503B threads from 2024 and half of it aged badly
reading 503B threads from 2024 and half of it aged badly. I have gone back and forth on this for months. The five questions worth asking before you commit to any compounded arrangement. Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the…
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Correction: patient-specific refers to the prescription, not to a bespoke formulation.
Agreed — and the follow-up question is what the beyond-use date is based on.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
the pharmacy and the prescriber are two separate questions
shortage status changes and the whole arrangement changes with it
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
compounded is not generic, there is no equivalence claim